Stockrabit · Analysts
Questions across 3 calls

Atirek Roy

Firm not listed in source transcripts

Neuland Laboratories Limited

Neuland Laboratories Limited CC-Mar24.pdf · 2024-05-14
So my first question is considering 3 points, we hav e not lost any customer in the past. Our custom manufacturing customers patent will not expire till 2030. It is difficult to switch the supplier after the molecule gets commercialized. Will it be fair to assume that our commercialized API and intermediate count will increase quarter-on-quarter for at least 2 years?
Yes, I was talking about commercialized API, not about registration and phase one phase two API's so will our commercialized API are counting to this quarter-on-quarter.